Save Product
Product Details
Synonym
CD80, B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7
Source
Human B7-1, His Tag (B71-H5228) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # P33681-1).
Predicted N-terminus: Val 35
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.8 kDa. The protein migrates as 40-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human B7-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human B7-1, His Tag (Cat. No. B71-H5228) is more than 95% and the molecular weight of this protein is around 38-55 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 10 μg/mL (100 μL/well) can bind Human B7-1, His Tag (Cat. No. B71-H5228) with a linear range of 0.078-1.25 μg/mL (QC tested).
Protocol
Bioactivity-SPR
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 18 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Human / Cynomolgus / Rhesus macaque CD28, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD8-H52A5) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 2.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 0.52 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Recent Advances
Drug Development Progress- English Name：
Cluster of differentiation 80
- Category：
- Approved Drugs：
2 Details
- Drugs in Clinical Trials：
10 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
